Literature DB >> 15309328

A listing of human tumor antigens recognized by T cells: March 2004 update.

Luisa Novellino1, Chiara Castelli, Giorgio Parmiani.   

Abstract

The technological advances occurred in the last few years have led to a great increase in the number of tumor associated antigens (TAA) that are currently available for clinical applications. In this review we provide a comprehensive list of human tumor antigens as reported in the literature updated at February 2004. The list includes all T cell-defined epitopes, while excluding analogs or artificially modified epitopes, as well as virus-encoded and antibodies-recognized antigens. TAAs are listed in alphabetical order along with the epitope sequence and the HLA allele which restricts recognition by T cells. Data on the tissue distribution of each antigen are also provided together with an extensive bibliography that allows a rapid search for any additional information may be needed on each single antigen or epitope. Overall, the updated list is a database tool for clinicians, scientists and students who have an interest in the field of tumor immunology and immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15309328     DOI: 10.1007/s00262-004-0560-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  113 in total

Review 1.  Macrophages as mediators of tumor immunosurveillance.

Authors:  Siddhartha Jaiswal; Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Trends Immunol       Date:  2010-05-07       Impact factor: 16.687

2.  Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.

Authors:  Philipp Beckhove; Rolf Warta; Britt Lemke; Diana Stoycheva; Frank Momburg; Martina Schnölzer; Uwe Warnken; Hubertus Schmitz-Winnenthal; Rezvan Ahmadi; Gerhard Dyckhoff; Mariana Bucur; Simone Jünger; Thomas Schueler; Volker Lennerz; Thomas Woelfel; Andreas Unterberg; Christel Herold-Mende
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

Review 3.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

4.  Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer.

Authors:  Xinqiang Hong; Tiangen Dong; Jianwei Hu; Tuo Yi; Wenxiang Li; Zhen Zhang; Shengli Lin; Weixin Niu
Journal:  Int J Colorectal Dis       Date:  2012-07-10       Impact factor: 2.571

5.  Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.

Authors:  Zeyu Xiong; Yan Yan; Enli Liu; Richard T Silver; Srdan Verstovsek; Fan Yang; Hong Wang; Josef Prchal; Xiao-Feng Yang
Journal:  Clin Immunol       Date:  2006-11-17       Impact factor: 3.969

Review 6.  Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance.

Authors:  Robert L Ferris; Jennifer L Hunt; Soldano Ferrone
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  Soluble plasma HLA peptidome as a potential source for cancer biomarkers.

Authors:  Michal Bassani-Sternberg; Eilon Barnea; Ilan Beer; Irit Avivi; Tami Katz; Arie Admon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

Review 8.  Prospects and challenges of building a cancer vaccine targeting telomerase.

Authors:  Robert H Vonderheide
Journal:  Biochimie       Date:  2007-07-17       Impact factor: 4.079

Review 9.  Peptide-based vaccines for cancer therapy.

Authors:  Giorgio Parmiani; Vincenzo Russo; Cristina Maccalli; Danilo Parolini; Nathalie Rizzo; Michele Maio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 10.  Immunotherapy of childhood cancer: from biologic understanding to clinical application.

Authors:  Alan S Wayne; Christian M Capitini; Crystal L Mackall
Journal:  Curr Opin Pediatr       Date:  2010-02       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.